Their study demonstrates that specifically inhibiting MMP-9 did not cause musculoskeletal syndrome, which is a common side effect of broad-spectrum MMP inhibitors, in a rat model and, additionally, they discovered that inhibiting MMP-9 resulted in a decrease in tumor development and the occurrence of metastases in a surgical orthotopic xenograft model of CRC. The gene discussed is MMP9; the disease is neoplasm.